Received by email:

File: Supreme Closes Final Tranch Monday November 17, 2014.pdf


  


                                                                              430 � 580 Hornby Street,
                                                                                        Vancouver BC
                                                                                              V6C 3B6
                                                                                 Phone: (604) 674-2191

                                                                             Email: info@supreme.ca
                                                                             Website: www.supreme.ca
Listed
  on
  the
  CSE
  under
  the
  symbol
  ("SL")
_________________________________________________________________________________________________________
  

NOT
  FOR
  DISSEMINATION
  IN
  THE
  UNITED
  STATES.
  FAILURE
  TO
  COMPLY
  WITH
  THIS
  
RESTRICTION
  MAY
  CONSTITUTE
  A
  VIOLATION
  OF
  UNITED
  STATES
  SECURITIES
  LAW.
  
                                                 
  
   SUPREME
  COMPLETES
  PRIVATE
  PLACEMENT
  FOR
  AGGREGATE
  TOTAL
  OF
  $1.78M
  
                                                 
  
November 17, 2014, Vancouver, BC � Supreme Pharmaceuticals Inc. ("Supreme" or the
"Company") (SL:CSE) is pleased to announce that it has closed the final tranche of its previously
announced unit financing for gross proceeds of $815,893.44 (the "Financing"). At the final
closing, Supreme issued 2,549,667 units (comprised of 2,549,667 common shares of the
Company ("Common Shares") and 1,274,834 Common Share purchase warrants ("Warrants"))
at a price of $0.32 per unit. Each Warrant is exercisable for one Common Share at a price of
$0.50 per share prior to November 17, 2016, subject to an accelerated expiry period upon 30-days
notice by the Company to the subscriber, if the Common Shares trade at or above $0.70 for any
five (5) day period during the term of the Warrants. In aggregate, total gross proceeds raised
from the first and second closings totalled $1,781,642.24 through the issuance of 5,567,632
Common Shares and 2,783,816 Warrants.

"Having raised almost double the proceeds that we initially sought when we announced our raise
just three weeks ago, we're pleased with the positive response we've had, and extremely gratified
at the investment community's ongoing interest in Supreme", stated a director of the company.
"With this raise now finalized, we have a strong balance sheet and are well-positioned to continue
executing on our long-term growth strategy."

The Company paid aggregate finder's fees of $21,769.60 and issued 68,030 Warrants to certain
arm's-length parties in the connection with the subscriptions of certain subscribers who
participated in the Financing.

The Common Shares and Warrants issued pursuant to the final tranche of the Financing are
subject to a hold period that expires March 18, 2015. Following closing, Supreme has 76,031,197
Common Shares issued and outstanding.

The Company intends to use the aggregate proceeds of the Financing for the continuing
development of the Company's Kincardine facility and general working capital purposes.

Contact Information

Investor Relations
430 � 580 Hornby Street, Vancouver BC




  
CALGARY:
  2395376v2
  

  
 
  


V6C 3B6
Phone: (604) 674-2191
Email: info@supreme.ca
Website: www.supreme.ca


FORWARD-LOOKING INFORMATION

This news release contains forward-looking statements and forward-looking information within the meaning of
applicable securities laws. These statements relate to future events or future performance. All statements other than
statements of historical fact may be forward-looking statements or information. More particularly and without
limitation, this news release contains forward-looking statements and information relating to the use of proceeds of t
--->he
Financing, as well as the Company's corporate strategy. The forward-looking statements and information are based on
certain key expectations and assumptions made by management of the Company, including, without limitation, the
Company's ability to carry out its business plan following the issuance of the required licenses by Health Canada.
Although management of the Company believes that the expectations and assumptions on which such forward-looking
statements and information are based are reasonable, undue reliance should not be placed on the forward-looking
statements and information since no assurance can be given that they will prove to be correct.

Forward-looking statements and information are provided for the purpose of providing information about the current
expectations and plans of management of the Company relating to the future. Readers are cautioned that reliance on
such statements and information may not be appropriate for other purposes, such as making investment decisions. Since
forward-looking statements and information address future events and conditions, by their very nature they involve
inherent risks and uncertainties. Actual results could differ materially from those currently anticipated due to a num
--->ber
of factors and risks. These include, but are not limited to, the Company's ability to identify and complete additional
suitable acquisitions to further the Company's growth as well as risks associated with the medical marijuana industry 
--->in
general such as operational risks in development and production delays or changes in plans with respect to
development projects or capital expenditures; the uncertainty of the capital markets; the uncertainty of receiving the
required licenses, production, costs and expenses; health, safety and environmental risks; marketing and transportatio
--->n;
loss of markets; environmental risks; competition; incorrect assessment of the value of the potential market; ability 
--->to
access sufficient capital from internal and external sources; failure to obtain required regulatory and other approval
--->s
and changes in legislation, including but not limited to tax laws and related regulations. Accordingly, readers should
not place undue reliance on the forward-looking statements, timelines and information contained in this news release.
Readers are cautioned that the foregoing list of factors is not exhaustive.

The forward-looking statements and information contained in this news release are made as of the date hereof and no
undertaking is given to update publicly or revise any forward-looking statements or information, whether as a result o
--->f
new information, future events or otherwise, unless so required by applicable securities laws or the Canadian Securiti
--->es
Exchange. The forward-looking statements or information contained in this news release are expressly qualified by this
cautionary statement.

  





  
CALGARY:
  2395376v2